In conclusion, our results on a consecutive ambulatory population of COVID‐19 cases suggest that blood level of MPO‐DNA complexes could be a useful biomarker of the early phase of SARS‐CoV‐2 infection. If further studies confirm that the dramatic production of NETs is a pathological mechanism of innate immunity involved in early step of SARS‐CoV‐2 infection, our data could open therapeutic perspectives by targeting NET production with inhibitors already tested in other lung infectious diseases